Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast

Rhea-AI Summary

Vivani Medical (NASDAQ: VANI) announced its participation in the Innovation in Obesity Therapeutics Summit West Coast in San Diego from December 10-12, 2024. CEO Adam Mendelsohn will engage in two key sessions:

1. A panel discussion on 'The Obesity Race on the Manufacturing Floor' on December 11 at 2:40 PM PT, addressing supply chain challenges for GLP-1 drugs alongside executives from Regor Therapeutics and Biolexis Therapeutics.

2. A presentation at 4:20 PM PT focusing on the company's NanoPortal™ implant technology and their lead program NPM-119, a six-month GLP-1 (exenatide) implant for chronic weight management. The implants are designed for once or twice-yearly dosing to improve medication adherence and patient tolerability. Clinical data from the LIBERATE-1 study is expected in 2025.

ALAMEDA, Calif.--(BUSINESS WIRE)-- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the Innovation in Obesity Therapeutics Summit West Coast, taking place in San Diego, California, from December 10-12, 2024.

Event details are as follows:

Panel Discussion: The Obesity Race on the Manufacturing Floor – Exploring Supply Challenges with Innovations in Discovery
Panel Date: Wednesday, December 11, 2024
Panel Time: 2:40 pm, Pacific Time

Dr. Mendelsohn will be joined by Feng Liu, Executive Director at Regor Therapeutics, and David Bearss, co-founder and Chairman at Biolexis Therapeutics, in a panel discussion of supply chain challenges for GLP-1 drugs and the innovative solutions that are being explored to address these issues.

Presentation: Advancing Chronic Disease Management with Ultra Long-Acting Miniature Subdermal Implants of GLP-1
Presentation Date: Wednesday, December 11, 2024
Presentation Time: 4:20pm, Pacific Time

In this session, Dr. Mendelsohn will provide an overview of Vivani’s emerging portfolio of miniature, drug implant candidates designed to revolutionize the treatment of chronic diseases by leveraging the company’s proprietary NanoPortal™ implant technology. The Company’s lead program, NPM-119, is a six-month GLP-1 (exenatide) implant in development for chronic weight management. Clinical data from LIBERATE-1, the first-in-human, study in obese and overweight individuals, is expected in 2025. These ultra long-acting implants are designed for once or twice-yearly dosing and directly address main [major] challenges to optimal treatment, including poor medication adherence and potentially poor patient tolerability.

More information about Innovation in Obesity Therapeutics Summit West Coast can be found at https://innovation-obesity-summit.com/.

About Vivani Medical, Inc.

Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Vivani’s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals. Vivani’s emerging pipeline also includes the NPM-139 (semaglutide implant) which is also under development for chronic weight management in obese and overweight individuals. The semaglutide implant has the added potential benefit of once-yearly administration. NPM-119 refers to the Company’s type 2 diabetes development program utilizing a six-month, subdermal exenatide implant. Both the NPM-115 and NPM-119 programs utilize exenatide-based products with a higher-dose associated with the NPM-115 program for chronic weight management in obese or overweight patients. These NanoPortal™ implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. Medication non-adherence, which contributes to more than $500 billion in annual avoidable healthcare costs and 125,000 potentially preventable deaths annually in the U.S. alone, is a primary and daunting reason obese or overweight patients, and patients taking type 2 diabetes or other chronic disease treatments face significant challenges in achieving positive real-world effectiveness. While the current GLP-1 landscape includes over 50 new molecular entities under clinical stage development, Vivani remains confident that its highly differentiated portfolio of miniature long-acting GLP-1 implants have the potential to provide an attractive therapeutic option for patients, prescribers and payers.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential thereof, the planned development therefor, the initiation of the LIBERATE-1 trial and reporting of trial results, Vivani’s emerging development plans for NPM-115, NPM-139, or Vivani’s plans with respect to Cortigent and its proposed initial public offering, technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani’s products, including NPM-115 and NPM-119; delays and changes in the development of Vivani’s products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani’s development activities, including Vivani’s ability to commence clinical development of NPM-119; risks related to the initiation, enrollment and conduct of Vivani’s planned clinical trials and the results therefrom; Vivani’s history of losses and Vivani’s ability to access additional capital or otherwise fund Vivani’s business; market conditions and the ability of Cortigent to complete its initial public offering. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission filed on March 26, 2024, as updated by the Company’s subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204260216/en/

Company Contact:

Donald Dwyer

Chief Business Officer

info@vivani.com

(415) 506-8462



Investor Relations Contact:

Jami Taylor

Investor Relations Advisor

investors@vivani.com

(415) 506-8462



Media Contact:

Sean Leous

ICR Healthcare

Sean.Leous@westwicke.com

(646) 866-4012

Source: Vivani Medical, Inc.

FAQ

What is Vivani Medical's NPM-119 and when will clinical data be available?

NPM-119 is Vivani Medical's six-month GLP-1 (exenatide) implant for chronic weight management. Clinical data from the LIBERATE-1 first-in-human study is expected in 2025.

When and where is Vivani Medical (VANI) presenting at the Obesity Therapeutics Summit?

Vivani Medical is presenting on December 11, 2024, at 4:20 PM PT at the Innovation in Obesity Therapeutics Summit West Coast in San Diego, California.

What is the purpose of Vivani Medical's NanoPortal implant technology?

The NanoPortal implant technology is designed for once or twice-yearly dosing to improve medication adherence and patient tolerability in chronic disease treatment through ultra long-acting miniature subdermal implants.

What supply chain challenges will be discussed in Vivani's (VANI) panel session?

The panel will discuss supply chain challenges for GLP-1 drugs and innovative solutions being explored to address these issues in the obesity therapeutics industry.